Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses

• Published in: The Journal of urology Vol. 168; no. 4 Pt 1; p. 1332
• Main Authors: Brock, Gerald B, McMahon, Chris G, Chen, K K, Costigan, Timothy, Shen, Wei, Watkins, Vish, Anglin, Greg, Whitaker, Steve
• Format: Journal Article
• Language: English
• Published: United States 01.10.2002
• Subjects: 3',5'-Cyclic-GMP Phosphodiesterases; Adult; Aged; Aged, 80 and over; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Double-Blind Method; Erectile Dysfunction - drug therapy; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors - adverse effects; Phosphodiesterase Inhibitors - therapeutic use; Phosphoric Diester Hydrolases - metabolism; Tadalafil; Treatment Outcome

We conducted integrated analyses of the efficacy and safety of tadalafil, a potent, selective phosphodiesterase 5 inhibitor, for the treatment of erectile dysfunction. A total of 1,112 men with a mean age of 59 years (range 22 to 82) and mild to severe erectile dysfunction of various etiologies were...